Treatment of Prolactinoma in Men with Macroprolactinoma and Hypogonadotrophic Hypogonadism
Clinical Scenario
This protocol addresses male patients diagnosed with a macroprolactinoma who present with hypogonadotrophic hypogonadism. Presenting features include gynaecomastia, loss of libido, erectile dysfunction, infertility, or galactorrhoea.
Why This Population Matters
Men presenting with any of these features should be evaluated for hyperprolactinaemia and a prolactin-secreting adenoma. Macroprolactinomas in men tend to be more aggressive and may show lower response rates than in women, making appropriate first-line management especially important.
Treatment Approach
Dopamine agonist therapy is the recommended first-line approach in this setting, preferred regardless of tumour size or degree of invasion. The full protocol specifies agent selection and the complete management pathway.
Dosage, monitoring schedule, and the complete treatment algorithm are available in the structured protocol — not shown here.
Treatment Goals
- Normalisation of serum prolactin levels
- Substantial reduction in tumour mass
- Improvement in visual fields where affected
References
DOI: 10.1038/s41574-023-00886-5
- Men with hypogonadotrophic hypogonadism presenting with gynaecomastia, loss of libido, erectile dysfunction and infertility or with galactorrhoea should be evaluated for hyperprolactinaemia and a prolactin-secreting adenoma (strong).
- Macroprolactinomas in men are more aggressive and show lower response rates to dopamine agonist therapy than in women (strong).
- Treatment with dopamine agonists is preferred regardless of size or invasion.
- Cabergoline is the preferred dopamine agonist owing to its long half-life, high efficacy and good tolerability (strong).
View source ↗